CD19 and mantle cell lymphoma: Due to the limited number of studies on bispecific and other targets of CAR-T therapy for MCL, and differences in targets and manufacturing processes compared to CD19 single-target CAR-T, this study excluded dual-target and case series with fewer than 10 patients to reduce heterogeneity and bias.